Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Clinical trial NCT07006727 · RECRUITING

Trial details

NCT number: NCT07006727
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Small Cell Lung Carcinoma Large Cell Neuroendocrine Carcinoma of the Lung Neuroendocrine Prostate Cancer Gastroenteropancreatic Neuroendocrine Carcinoma

Start date: 2025-10-16
Primary completion: 2031-08-29
Enrollment: 116

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.